Low-cost, point-of-care biomarker quantification

Piorino, Fernanda; Patterson, Alexandra T; Styczynski, Mark P.

doi:10.1016/j.copbio.2022.102738

Cited by 13 publications

(5 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diagnostics are a vital part of the healthcare infrastructure, with substantial impacts on the treatment of individual patients, as well as public health policy [ 34 ]. eNose technology meets the main requirements of this type of technique.…”

Section: Discussionmentioning

confidence: 99%

Low-Cost Electronic Nose for the Determination of Urinary Infections

de la Rica-Martinez,

Martínez-Muñoz,

Sanjuan

et al. 2023

Sensors

View full text Add to dashboard Cite

Currently, urine samples for bacterial or fungal infections require a long diagnostic period (48 h). In the present work, a point-of-care device known as an electronic nose (eNose) has been designed based on the “smell print” of infections, since each one emits various volatile organic compounds (VOC) that can be registered by the electronic systems of the device and recognized in a very short time. Urine samples were analyzed in parallel using urine culture and eNose technology. A total of 203 urine samples were analyzed, of which 106 were infected and 97 were not infected. A principal component analysis (PCA) was performed using these data. The algorithm was initially capable of correctly classifying 49% of the total samples. By using SVM-based models, it is possible to improve the accuracy of the classification up to 74% when randomly using 85% of the data for training and 15% for validation. The model is evaluated as having a correct classification rate of 74%. In conclusion, the diagnostic accuracy of the eNose in urine samples is high, promising and amenable for further improvement, and the eNose has the potential to become a feasible, reproducible, low-cost and high-precision device to be applied in clinical practice for the diagnosis of urinary tract infections.

show abstract

Section: Discussionmentioning

confidence: 99%

Low-Cost Electronic Nose for the Determination of Urinary Infections

de la Rica-Martinez,

Martínez-Muñoz,

Sanjuan

et al. 2023

Sensors

View full text Add to dashboard Cite

show abstract

“…In some cases, such as Nefrocheck or PSP, they have the possibility of their own biomarker; or others, such as NEXUS IB10, offer the possibility of having numerous biomarkers such as NT-ProBNP, Troponin, DPP3, BioADM, etc., using different discs for each. The possibility of having biomarkers at the bedside, combined with the best knowledge and use of the means usually available, will undoubtedly improve the speed and accuracy of care [ 128 ].…”

Section: The Best Biomarkers In Intensive and Perioperative Carementioning

confidence: 99%

Biomarkers as Prognostic Predictors and Therapeutic Guide in Critically Ill Patients: Clinical Evidence

Hernández

Rueda

2023

JPM

View full text Add to dashboard Cite

A biomarker is a molecule that can be measured in a biological sample in an objective, systematic, and precise way, whose levels indicate whether a process is normal or pathological. Knowing the most important biomarkers and their characteristics is the key to precision medicine in intensive and perioperative care. Biomarkers can be used to diagnose, in assessment of disease severity, to stratify risk, to predict and guide clinical decisions, and to guide treatments and response to them. In this review, we will analyze what characteristics a biomarker should have and how to ensure its usefulness, and we will review the biomarkers that in our opinion can make their knowledge more useful to the reader in their clinical practice, with a future perspective. These biomarkers, in our opinion, are lactate, C-Reactive Protein, Troponins T and I, Brain Natriuretic Peptides, Procalcitonin, MR-ProAdrenomedullin and BioAdrenomedullin, Neutrophil/lymphocyte ratio and lymphopenia, Proenkephalin, NefroCheck, Neutrophil gelatinase-associated lipocalin (NGAL), Interleukin 6, Urokinase-type soluble plasminogen activator receptor (suPAR), Presepsin, Pancreatic Stone Protein (PSP), and Dipeptidyl peptidase 3 (DPP3). Finally, we propose an approach to the perioperative evaluation of high-risk patients and critically ill patients in the Intensive Care Unit (ICU) based on biomarkers.

show abstract

“… 2 Furthermore, the pain associated with blood sampling can deter individuals with needle or blood phobias from getting tested. 1 Urine and saliva are less invasive and easier to collect; however, these fluids contain only subsets of the biomarkers found in blood, 3 typically at significantly lower concentrations, 4 hindering their use for many diagnostic applications. 5 …”

Section: Introductionmentioning

confidence: 99%

Microneedle-based sampling of dermal interstitial fluid using a vacuum-assisted skin patch

Jiang,

Wilkirson,

Bailey

et al. 2024

Cell Reports Physical Science

View full text Add to dashboard Cite

Low-cost, point-of-care biomarker quantification

Cited by 13 publications

References 54 publications

Low-Cost Electronic Nose for the Determination of Urinary Infections

Low-Cost Electronic Nose for the Determination of Urinary Infections

Biomarkers as Prognostic Predictors and Therapeutic Guide in Critically Ill Patients: Clinical Evidence

Microneedle-based sampling of dermal interstitial fluid using a vacuum-assisted skin patch

Contact Info

Product

Resources

About